Amer Ali A, Karkar Yasir, Bingle Lewis, Elkordy Amal Ali, Chaw Cheng Shu
School of Pharmacy and Pharmaceutical Sciences, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland SR1 3SD, UK.
School of Nursing and Health Sciences, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland SR1 3SD, UK.
Molecules. 2025 Sep 12;30(18):3715. doi: 10.3390/molecules30183715.
Nisin, a food preservative lantibiotic produced by , exhibits potent antimicrobial activity against a wide range of Gram-positive pathogens, including antibiotic-resistant strains such as methicillin-resistant (MRSA). This study explores the development of a novel nano drug delivery platform comprising nisin-loaded niosomes, formulated via microfluidic mixing, and integrated into fast-dissolving oral films for targeted buccal administration. Microfluidic synthesis enabled the precise control of critical parameters including the flow rate ratio, surfactant composition, and lipid concentration, resulting in uniform niosomal vesicles with optimal size distribution (100-200 nm), low polydispersity index, and high encapsulation efficiency. Span 40 and Span 60 were employed as non-ionic surfactants, stabilized with cholesterol to improve bilayer rigidity and drug retention. The encapsulated nisin demonstrated improved physicochemical stability over time and protection against proteolytic degradation, thus preserving its antimicrobial potency. The niosomal suspensions were subsequently incorporated into polymer-based oral films as a final dosage form composed of polyvinyl alcohol (PVA) as the primary film-forming polymer, polyethylene glycol 400 (PEG400) as a plasticizer, and sucralose and mint as a sweetener and flavoring agent, respectively. A disintegrant was added to accelerate film dissolution in the oral cavity, facilitating the rapid release of niosomal nisin. The films were cast and evaluated for thickness uniformity, mechanical properties, disintegration time, surface morphology, and drug content uniformity. The dried films exhibited desirable flexibility, rapid disintegration (<30 s), and consistent distribution of nisin-loaded vesicles. In vitro antimicrobial assays confirmed that the bioactivity of nisin was retained post-formulation, showing effective inhibition zones (16 mm) against . This delivery system offers a promising platform for localized antimicrobial therapy in the oral cavity, potentially aiding in the treatment of dental plaque, oral infections, and periodontal diseases. Overall, the integration of microfluidic-synthesized nisin niosomes into oral films presents a novel, non-invasive strategy for enhancing the stability and therapeutic efficacy of peptide-based drugs in mucosal environments. Physicochemical characterization of the niosomes and niosome films was performed using Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) to evaluate thermal stability and scanning electron microscopy (SEM) to assess surface morphology. In vitro peptide release studies demonstrated sustained release from both niosomal suspensions and film matrices, and the resulting data were further fitted to established kinetic models to elucidate the underlying drug release mechanisms. This delivery system offers a promising platform for localized antimicrobial therapy in the oral cavity, potentially aiding in the treatment of dental plaque, oral infections, and periodontal diseases. Overall, the integration of microfluidic-synthesized nisin niosomes into oral films presents a novel, non-invasive strategy for enhancing the stability and therapeutic efficacy of peptide-based drugs in mucosal environments.
乳酸链球菌素是一种由[具体产生菌]产生的食品防腐剂羊毛硫抗生素,对多种革兰氏阳性病原体具有强大的抗菌活性,包括耐抗生素菌株,如耐甲氧西林金黄色葡萄球菌(MRSA)。本研究探索了一种新型纳米药物递送平台的开发,该平台由通过微流混合配制的载有乳酸链球菌素的脂质体组成,并整合到用于靶向口腔给药的速溶口腔膜中。微流合成能够精确控制关键参数,包括流速比、表面活性剂组成和脂质浓度,从而产生具有最佳尺寸分布(100 - 200 nm)、低多分散指数和高包封效率的均匀脂质体囊泡。司盘40和司盘60被用作非离子表面活性剂,用胆固醇稳定以提高双层刚性和药物保留率。包封的乳酸链球菌素随时间表现出改善的物理化学稳定性,并能防止蛋白水解降解,从而保留其抗菌效力。随后将脂质体悬浮液掺入基于聚合物的口腔膜中,作为最终剂型,该剂型以聚乙烯醇(PVA)作为主要成膜聚合物,聚乙二醇400(PEG400)作为增塑剂,分别以三氯蔗糖和薄荷作为甜味剂和调味剂。加入崩解剂以加速膜在口腔中的溶解,促进脂质体包裹的乳酸链球菌素的快速释放。对膜进行浇铸并评估其厚度均匀性、机械性能、崩解时间、表面形态和药物含量均匀性。干燥后的膜表现出理想的柔韧性、快速崩解(<30秒)以及载有乳酸链球菌素囊泡的均匀分布。体外抗菌试验证实,乳酸链球菌素在制剂后仍保留生物活性,对[具体菌株]显示出有效的抑菌圈(16 mm)。该递送系统为口腔局部抗菌治疗提供了一个有前景的平台,可能有助于治疗牙菌斑、口腔感染和牙周疾病。总体而言,将微流合成的乳酸链球菌素脂质体整合到口腔膜中,为增强基于肽的药物在粘膜环境中的稳定性和治疗效果提供了一种新颖的非侵入性策略。使用傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)和热重分析(TGA)对脂质体和脂质体膜进行物理化学表征,以评估热稳定性,并使用扫描电子显微镜(SEM)评估表面形态。体外肽释放研究表明,脂质体悬浮液和膜基质均呈现持续释放,所得数据进一步拟合到已建立的动力学模型以阐明潜在的药物释放机制。该递送系统为口腔局部抗菌治疗提供了一个有前景的平台,可能有助于治疗牙菌斑、口腔感染和牙周疾病。总体而言,将微流合成的乳酸链球菌素脂质体整合到口腔膜中,为增强基于肽的药物在粘膜环境中的稳定性和治疗效果提供了一种新颖的非侵入性策略。